Latest Hospital for Special Surgery Stories

Together Voice Critical Need for Federal Appropriations to Support Lupus Research and Advance New Treatments WASHINGTON, March 19, 2013 /PRNewswire-USNewswire/ -- America's leading proponents for lupus research came together today to host a Congressional briefing to update the U.S. Senate and House of Representatives on the pressing needs of the 1.5 million Americans living with lupus -- the prototypical autoimmune disease. As sequestration imminently threatens funding for...

A recent deal signed with Health First strengthens Intellum's presence and increases its impact in the healthcare field. Atlanta, GA (PRWEB) February 25, 2013 Health First recently signed an agreement to launch Intellum's EXCEED LMS for their Learning & Development department, thus supporting their strive for innovative technologies. Michele Grant Chetwynd (Health First's LMS Administrator) stated it was Matt Gilley's (Intellum's Chief Engagement Officer)...

A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis. The treatment improved pain and function, and in up to 73% of patients, appeared to delay the progression of osteoarthritis, which is a progressive disease. The study appears online, ahead of print, in the Clinical Journal of Sports Medicine. "This is a very positive study," said Brian Halpern, M.D., chief of the Primary Care...

NEW YORK, Jan. 31, 2013 /PRNewswire/ -- The Lupus Research Institute (LRI) - world's leading supporter of innovative research in lupus -- today awards $3.6 million in Novel Research Grants to allow 12 investigators to pursue ground-breaking studies with potential for transformative results. The $300,000 grants provide scientists with the resources to devote their talent to lupus research for three years. In just its first decade of service, the LRI has awarded more than $40 million...

Hospital for Special Surgery Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in...

NEW YORK, Nov. 30, 2012 /PRNewswire/ -- For the fourth year in a row, Hospital for Special Surgery has an infection rate that is significantly lower than the New York State average for hip replacement or revision surgeries, according to the 2011 report on hospital infection rates just released by the State Department of Health. "It is vital to a patient's well-being that they are aware of a center's infection rate when choosing where to have surgery," said Louis A. Shapiro,...

May provide treatment option for those with harder-to-treat memory problems, skin ulcers and kidney disease Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal...

New research suggests that statins, traditionally used for cholesterol lowering, could be used in the management of individuals who are at risk for developing clotting because they have autoimmune antiphospholipid antibodies (aPL). The research will be presented in two presentations at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP). The meeting will be held Nov. 9-14, in Washington D.C. "What we have shown is that...

For years, researchers have known that antiphospholipid antibodies (aPLs) can cause pregnancy loss and clotting, but they haven't known the true scope of the problem. Now a new study provides the first estimates of the prevalence of these antibodies in patients suffering from pregnancy loss, stroke, myocardial infarction, and deep vein thrombosis. "Based on the available data, our best estimate is that around 10 to 15% of clotting disorders are associated with autoimmune antiphospholipid...

A randomized, double-blind clinical trial by researchers at Hospital for Special Surgery has revealed that corticosteroids are more effective than the more expensive treatment, hylan G-F 20 (Synvisc One, Genzyme Biosurgery), in providing pain relief to patients with thumb arthritis. The study also showed that both of these commonly used treatments provided clinically meaningful pain relief, but so did a placebo injection. "On average, each of the therapies resulted in clinically meaningful...